ELP3 and CTU1/2 were shown to enhance glycolysis in melanoma cells by up-regulating hypoxia-inducible factor 1 subunit alpha (HIF1A) translation through codon-dependent regulation, contributing to their resistance to RAF inhibitors such as vemurafenib or dabrafenib (106,142). Here, HIF1A is linked to melanoma.